Qube Research & Technologies (QRT)
CLDX icon

Qube Research & Technologies (QRT)’s Celldex Therapeutics CLDX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125,506
Closed -$4.64M – 3407
2024
Q2 		$4.64M Sell
125,506
-80,658
-39% -$3.04M 0.01% 1291
2024
Q1 		$8.65M Buy
206,164
+161,196
+358% +$6.62M 0.01% 925
2023
Q4 		$1.78M Buy
44,968
+40,669
+946% +$1.2M ﹤0.01% 1581
2023
Q3 		$118K Sell
4,299
-64,548
-94% -$2.02M ﹤0.01% 2609
2023
Q2 		$2.34M Buy
68,847
+6,902
+11% +$233K 0.01% 987
2023
Q1 		$2.23M Buy
61,945
+28,271
+84% +$1.22M 0.01% 957
2022
Q4 		$1.5M Buy
33,674
+26,198
+350% +$935K 0.01% 1049
2022
Q3 		$210K Buy
+7,476
New +$229K ﹤0.01% 1759
2021
Q2 		– Sell
-64,913
Closed -$1.34M – 2320
2021
Q1 		$1.34M Sell
64,913
-106,405
-62% -$2.44M 0.02% 735
2020
Q4 		$3M Buy
171,318
+97,734
+133% +$1.76M 0.04% 464
2020
Q3 		$1.09M Buy
73,584
+37,250
+103% +$436K 0.02% 790
2020
Q2 		$472K Buy
+36,334
New +$161K 0.01% 1140

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CLDX Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 125,506 shares — an estimated $4.64M sold.

Qube Research & Technologies (QRT) first reported a position in CLDX in Q2 2020 and held it in 12 quarters. The position peaked at $8.65M in Q1 2024. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 125,506 Celldex Therapeutics shares in Q3 2024, an estimated $4.64M.
  • Qube Research & Technologies (QRT) first reported a position in Celldex Therapeutics in Q2 2020 and held it in 12 quarters.
  • Qube Research & Technologies (QRT)'s Celldex Therapeutics position peaked at $8.65M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.